HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cholestasis

Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
Also Known As:
Bile Duct Obstructions; Biliary Stases; Cholestases; Duct Obstruction, Bile; Duct Obstructions, Bile; Obstruction, Bile Duct; Obstructions, Bile Duct; Stases, Biliary; Stasis, Biliary; Bile Duct Obstruction; Biliary Stasis
Networked: 7937 relevant articles (463 outcomes, 785 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Pruritus (Itching)
2. Liver Diseases (Liver Disease)
3. Fibrosis (Cirrhosis)
4. Inflammation (Inflammations)
5. Necrosis

Experts

1. Trauner, Michael: 84 articles (12/2022 - 01/2002)
2. Fickert, Peter: 40 articles (12/2021 - 01/2002)
3. Boyer, James L: 39 articles (12/2022 - 01/2002)
4. Beuers, Ulrich: 39 articles (11/2021 - 05/2002)
5. Alpini, Gianfranco: 38 articles (11/2021 - 05/2002)
6. Roma, Marcelo G: 35 articles (04/2022 - 04/2002)
7. Glaser, Shannon: 32 articles (11/2021 - 05/2002)
8. Puder, Mark: 28 articles (01/2021 - 07/2006)
9. Marin, Jose J G: 27 articles (10/2022 - 09/2003)
10. Marzioni, Marco: 27 articles (10/2022 - 05/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cholestasis:
1. Ursodeoxycholic Acid (Urso)FDA LinkGeneric
2. Bile Acids and Salts (Bile Acids)IBA
3. BilirubinIBA
4. LipidsIBA
5. EnzymesIBA
6. Biomarkers (Surrogate Marker)IBA
7. Rifampin (Rifampicin)FDA LinkGeneric
8. Fish OilsIBA
01/01/2019 - "In infants with PNALD/cholestasis (any definition), use of fish oil-LEs was associated with significantly less cholestasis compared to the S-LE group (typical risk ratio (RR) 0.54, 95% confidence interval (CI) 0.32 to 0.91; typical risk difference (RD) -0.39, 95% CI -0.65 to -0.12; number needed to treat for additional beneficial outcome (NNTB) 3, 95% CI 2 to 9; 2 studies; n = 40; very low-quality evidence). "
01/01/2019 - " preterm infants with surgical conditions or cholestasis, there was only one small study each reporting no evidence of a difference in incidence or resolution of cholestasis respectively with use of a pure F-LE versus S-LE (using a Cbil cut-off of 2 mg/dL).In preterm infants with PNALD/cholestasis (using any definition), the meta-analysis showed significantly less cholestasis with the use of fish oil-LE compared to S-LE (typical RR 0.54, 95% CI 0.32 to 0.91; typical RD -0.39, 95% CI -0.65 to -0.12; number needed to treat for an additional beneficial outcome (NNTB) 3, 95% CI 2 to 9; 2 studies; n = 40; very low-quality evidence). "
01/01/2015 - "Fish oil-based IVLE, which is rich in n-3 PUFAs, may be effective in reversing hepatic cholestasis due to PNALD."
04/01/2010 - "Temporary elimination of SLE and supplementation with enteral fish oil improved cholestasis in PN-dependent infants. "
01/01/2019 - "Based on the current review, there is insufficient data from randomised studies to determine with any certainty, the potential benefit of any LE including fish oil-containing LEs over another LE, for prevention or resolution of PNALD/cholestasis or any other outcomes in term and late preterm infants with underlying surgical conditions or cholestasis. "
9. Proteins (Proteins, Gene)FDA Link
10. CholesterolIBA

Therapies and Procedures

1. Therapeutics
2. Parenteral Nutrition
3. Ligation
4. Liver Transplantation
5. Stents